In a unanimous decision yesterday, the U.S. Food and Drug Administration’s Dermatologic and Ophthalmic Drugs Advisory Committee recommended approval of a 125-µg dose of ThromboGenics’ ocriplasmin for ...

Ocriplasmin, a truncated form of the serine protease plasmin, has proteolytic activity against 2 major components of the vitreoretinal interface: fibronectin and laminin. The efficacy and safety of ...

In two ancillary studies of two multi-center international clinical trials, the injectable drug ocriplasmin appears to improve vision among patients suffering from symptomatic vitreomacular adhesion ...

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that Health Canada has ...

WAIKOLOA, Hawaii — Jetrea may not be as cost-effective as vitrectomy for vitreomacular adhesion and macular hole closure, a speaker told colleagues here. “You’ve got to decide what’s best for your ...

Vitreomacular adhesion (VMA) can lead to reduced visual acuity, metamorphopsia, photopsia, and micropsia. These symptoms are explained by vitreomacular traction (VMT) at the vitreomacular junction.

ThromboGenics has received FDA approval for a drug to treat symptomatic vitreomacular adhesion, according to a news release. The drug, Jetrea, is approved to treat the eye condition, which can ...

JETREA (ocriplasmin) 2.5mg/mL intravitreal injection by ThromboGenics The FDA has approved Jetrea (ocriplasmin; ThromboGeneics) for the treatment of symptomatic vitreomacular adhesion (VMA), a ...

LOS ANGELES -- In two ancillary studies of two multi-center international clinical trials led by the University of Southern California (USC) Eye Institute, the injectable drug ocriplasmin appears to ...